| 2939.19.10 | 00 | Papaverine and its salts | kg | Free | | 15.4￠/kg + 104% |
| 2939.19.20 | 00 | Synthetic | kg | Free | | 15.4￠/kg + 50% |
| 2939.20.00 | 10 | Quinine and its salts | g | | | |
| 2939.30.00 | 00 | Caffeine and its salts | kg | Free | | 59% |
| 2939.41.00 | 00 | Ephedrine and its salts | kg | Free | | 15.4￠/kg + 59% |
| 2939.42.00 | 00 | Pseudoephedrine and its salts | kg | Free | | 15.4￠/kg + 59% |
| 2939.43.00 | 00 | Cathine (INN) and its salts | kg | Free | | 15.4￠/kg + 59% |
| 2939.51.00 | 00 | Fenetylline (INN) and its salts | kg | Free | | 25% |
| 2939.61.00 | 00 | Ergometrine and its salts | kg | Free | | 25% |
| 2939.62.00 | 00 | Ergotamine and its salts | kg | Free | | 25% |
| 2939.63.00 | 00 | Lysergic acid and its salts | kg | Free | | 25% |
| 2940..00 | | XIII. OTHER ORGANIC COMPOUNDS | | | | |
| 2941.10.10 | 00 | Ampicillin and its salts | kg | Free | | 15.4￠/kg + 48.5% |
| 2941.10.20 | 00 | Penicillin G salts | kg | Free | | 15.4￠/kg + 49% |
| 2941.90.10 | 10 | Aminoglycoside antibiotics | kg | | | |
| 2941.90.30 | 00 | Aromatic or modified aromatic | kg | Free | | 15.4￠/kg + 45% |
| 2942.00.03 | 00 | [2,2'-Thiobis(4-(1,1,3,3-tetramethyl-n-butyl)- phenolato)(2,1)]-O,O',S-(1-butanamine), nickel II | kg | Free | | 15.4￠/kg + 46.5% |
| 2942.00.05 | 00 | Drugs | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4￠/kg + 46% |
| 2942.00.10 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 46.5% |
| 3001.20.00 | 00 | Extracts of glands or other organs or of their secretions | kg | Free | | 10% |
| 3002.10.01 | | Antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes | | Free | | Free |
| 3002.10.01 | 10 | Human blood plasma | kg | | | |
| 3002.10.01 | 30 | Human immune blood sera | kg | | | |
| 3002.90.10 | 00 | Ferments | kg | Free | | 25% |
| 3002.90.51 | 20 | Antiallergenic preparations | kg | | | |
